Syros Pharmaceuticals, Inc. (SYRS)
Largest Insider Buys in Sector
SYRS Stock Price History Chart
SYRS Stock Performance
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute …
Insider Activity of Syros Pharmaceuticals, Inc.
Over the last 12 months, insiders at Syros Pharmaceuticals, Inc. have bought $321,920 and sold $353,165 worth of Syros Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Syros Pharmaceuticals, Inc. have bought $1.51M and sold $1.97M worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $8M. Haas Jason (Chief Financial Officer) — $161,240. Chee Conley (President & CEO) — $160,680.
The last purchase of 45,344 shares for transaction amount of $76,006 was made by Haas Jason (Chief Financial Officer) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Syros Pharmaceuticals, Inc.
| 2024-12-02 | Sale | director | 37,070 0.1457% | $0.27 | $10,016 | -7.32% | ||
| 2024-11-25 | Sale | director | 134,713 0.5129% | $0.27 | $35,739 | -5.15% | ||
| 2024-11-19 | Sale | Chief Legal & Compliance Offic | 46,657 0.1328% | $0.22 | $10,321 | 0.00% | ||
| 2024-11-18 | Sale | Chief Development Officer | 36,133 0.149% | $0.22 | $7,949 | 0.00% | ||
| 2024-11-18 | Sale | Chief Medical Officer | 12,099 0.0447% | $0.20 | $2,382 | 0.00% | ||
| 2024-11-18 | Sale | Chief Financial Officer | 137,803 0.5433% | $0.21 | $28,980 | 0.00% | ||
| 2024-11-18 | Sale | President & CEO | 134,797 0.5049% | $0.20 | $26,932 | 0.00% | ||
| 2024-09-12 | Chief Financial Officer | 45,344 0.1811% | $1.68 | $76,006 | +23.57% | |||
| 2024-09-11 | President & CEO | 50,000 0.2049% | $1.71 | $85,420 | -8.10% | |||
| 2024-09-11 | Chief Financial Officer | 19,293 0.073% | $1.58 | $30,446 | -0.51% | |||
| 2024-09-10 | President & CEO | 50,000 0.1805% | $1.51 | $75,260 | +24.36% | |||
| 2024-09-10 | Chief Financial Officer | 35,363 0.1314% | $1.55 | $54,788 | +24.36% | |||
| 2024-06-28 | Sale | director | 34,837 0.1171% | $5.12 | $178,365 | 0.00% | ||
| 2024-04-03 | Sale | Chief Medical Officer | 10,451 0.0393% | $4.95 | $51,732 | -9.64% | ||
| 2024-04-02 | Sale | Chief Medical Officer | 150 0.0006% | $4.98 | $747 | -2.59% | ||
| 2023-12-21 | director | 904,977 3.271% | $4.42 | $4M | -10.58% | |||
| 2023-12-12 | Sale | Chief Medical Officer | 6,287 0.0339% | $4.95 | $31,121 | +9.83% | ||
| 2023-12-06 | Sale | Chief Medical Officer | 6,287 0.0291% | $3.95 | $24,834 | +31.25% | ||
| 2023-07-31 | Sale | Chief Medical Officer | 7,348 0.03% | $3.95 | $29,025 | +27.89% | ||
| 2023-07-17 | Sale | Chief Scientific Officer | 689 0.0025% | $3.50 | $2,412 | +42.33% |
Insider Historical Profitability
| Chee Conley | President & CEO | 0 0% | $0.20 | 2 | 1 | |
| Haas Jason | Chief Financial Officer | 0 0% | $0.20 | 3 | 1 | |
| NELSEN ROBERT | 4637137 17.2818% | $0.20 | 1 | 0 | <0.0001% | |
| ARCH Venture Fund VII, L.P. | 10 percent owner | 4242051 15.8094% | $0.20 | 1 | 9 | <0.0001% |
| Flagship Ventures Fund IV, L.P. | 10 percent owner | 3674660 13.6948% | $0.20 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bain Capital Life Sciences Investors Llc | $14.71M | 10.29 | 2.75M | 0% | +$0 | 1.18 | |
| Artal Group S A | $13.4M | 9.37 | 2.51M | 0% | +$0 | 0.06 | |
| Adage Capital Partners Gp L L C | $11.08M | 7.75 | 2.07M | 0% | +$0 | 0.02 | |
| Samsara Biocapital Llc | $9.56M | 6.68 | 1.79M | 0% | +$0 | 1.49 | |
| Avidity Partners Management Lp | $8.95M | 6.26 | 1.67M | 0% | +$0 | 0.34 |